Today's Daily Dose brings you news about Axovant's disappointing phase II trial in REM sleep behavior disorder; progress in Axsome Therapeutics' ADVANCE-1 study of Alzheimer's; Menlo Therapeutics' promising results from phase II trial of Serlopitant in pruritus associated with psoriasis, and Ra Pharma's generalized myasthenia gravis study results.
from RTT - Biotech https://ift.tt/2B6JMhg
via IFTTT
No comments:
Post a Comment